Securities Fraud Investigation Into Zimmer Biomet Holdings, Inc. (ZBH) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

Core Viewpoint - Zimmer Biomet Holdings, Inc. is under investigation for potential violations of federal securities laws following disappointing financial results and a significant drop in stock price [1][2]. Financial Performance - On November 5, 2025, Zimmer reported third quarter 2025 net sales of approximately $2 billion, attributed to weaknesses in Latin America, Emerging Markets in Europe, and non-core businesses [2]. - The company lowered its full-year organic revenue growth forecast from 4.5% to 4.0%, citing ongoing weakness in restorative therapies and a modest slowdown in the U.S. revision market for hips and knees [2]. Stock Market Reaction - Following the financial results announcement, Zimmer's stock price decreased by $15.63, or 15.2%, closing at $87.55 per share on November 5, 2025, resulting in losses for investors [2].